Use of the AST to platelet ratio index in HCV/HIV co-infected patients

Alimentary Pharmacology and Therapeutics

Volumn 33, Issue 5, 2011, Pages 566-577

  Singal, A G ^a   Thomassen, L V ^b   Gretch, D R ^b   Shuhart, M C ^b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTATE AMINOTRANSFERASE; VIRUS RNA;

ADULT; ANALYTICAL PARAMETERS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE TO PLATELET RATIO INDEX; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FEMALE; HEPATITIS C; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; PREDICTIVE VALUE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; VIRUS LOAD;

ADULT; ASPARTATE AMINOTRANSFERASES; BIOLOGICAL MARKERS; BIOPSY; FEMALE; HEPATITIS C; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PLATELET COUNT; PREDICTIVE VALUE OF TESTS; SEVERITY OF ILLNESS INDEX;

EID: 79251475259     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2010.04560.x     Document Type: Article

References (39)

1. Centers for Disease Control and Prevention. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR Recomm Rep 1998; 47: 1-39.
2. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ,. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006; 144: 705-14.
3. Kim WR,. The burden of hepatitis C in the United States. Hepatology 2002; 36 (5 Suppl. 1): S30-4.
4. Deuffic-Burban S, Poynard T, Sulkowski MS, Wong JB,. Estimating the future health burden of chronic hepatitis C and human immunodeficiency virus infections in the United States. J Viral Hepat 2007; 14: 107-15.
5. Tedeschi R, Pivetta E, Zanussi S, et al. Quantification of hepatitis C virus (HCV) in liver specimens and sera from patients with human immunodeficiency virus coinfection by using the Versant HCV RNA 3.0 (branched DNA-based) DNA assay. J Clin Microbiol 2003; 41: 3046-50.
6. Staples CT Jr, Rimland D, Dudas D,. Hepatitis C in the HIV (human immunodeficiency virus) Atlanta V.A. (Veterans Affairs Medical Center) Cohort Study (HAVACS): the effect of coinfection on survival. Clin Infect Dis 1999; 29: 150-4.
7. Sherman KE, Rouster SD, Chung RT, Rajicic N,. Hepatitis C virus prevalence among patients infected with human immunodeficiency virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group. Clin Infect Dis 2002; 34: 831-7.
8. Weber R, Friis-Moller N, Sabin C,. HIV and non-HIV Related Deaths and Their Relationship to Immunodeficiency: The D:A:D Study. In: Proceedings of the 12th Conference on Retroviruses and Opportunistic Infections. Boston, MA, February 2005 [Abstract 595].
9. Mohsen AH, Easterbrook PJ, Taylor C, et al. Impact of human immunodeficiency virus (HIV) infection on the progression of liver fibrosis in hepatitis C virus infected patients. Gut 2003; 52: 1035-40.
10. Graham CS, Baden LR, Yu E, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis 2001; 33: 562-9.
11. Puoti M, Bonacini M, Spinetti A, et al. Liver fibrosis progression is related to CD4 cell depletion in patients coinfected with hepatitis C virus and human immunodeficiency virus. J Infect Dis 2001; 183: 134-7.
12. Berenguer J, Alvarez-Pellicer J, Martin PM, et al. Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology (Baltimore, Md.) 2009; 50: 407-13.
13. Garcia-Tsao G, Boyer JL,. Outpatient liver biopsy: how safe is it? Ann Intern Med 1993; 118: 150-3.
14. Piccinino F, Sagnelli E, Pasquale G, Giusti G,. Complications following percutaneous liver biopsy. A multicentre retrospective study on 68,276 biopsies. J Hepatol 1986; 2: 165-73.
15. Strader DB, Wright T, Thomas DL, Seeff LB,. Diagnosis, management, and treatment of hepatitis C. Hepatology (Baltimore, Md.) 2004; 39: 1147-71.
16. Al-Mohri H, Cooper C, Murphy T, Klein MB,. Validation of a simple model for predicting liver fibrosis in HIV/hepatitis C virus-coinfected patients. HIV Med 2005; 6: 375-8.
17. Fontana RJ, Lok AS,. Noninvasive monitoring of patients with chronic hepatitis C. Hepatology (Baltimore, Md.) 2002; 36 (5 Suppl. 1): S57-64.
18. Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T,. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001; 357: 1069-75.
19. Forns X, Ampurdanes S, Llovet JM, et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology (Baltimore, Md.) 2002; 36 (4 Pt 1): 986-92.
20. Pohl A, Behling C, Oliver D, Kilani M, Monson P, Hassanein T,. Serum aminotransferase levels and platelet counts as predictors of degree of fibrosis in chronic hepatitis C virus infection. Am J Gastroenterol 2001; 96: 3142-6.
21. Poynard T, Bedossa P,. Age and platelet count: a simple index for predicting the presence of histological lesions in patients with antibodies to hepatitis C virus. METAVIR and CLINIVIR Cooperative Study Groups. J Viral Hepat 1997; 4: 199-208.
22. Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology (Baltimore, Md.) 2003; 38: 518-26.
23. Lok AS, Ghany MG, Goodman ZD, et al. Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: results of the HALT-C cohort. Hepatology (Baltimore, Md.) 2005; 42: 282-92.
24. Myers RP, Benhamou Y, Imbert-Bismut F, et al. Serum biochemical markers accurately predict liver fibrosis in HIV and hepatitis C virus co-infected patients. AIDS 2003; 17: 721-5.
25. Kelleher TB, Mehta SH, Bhaskar R, et al. Prediction of hepatic fibrosis in HIV/HCV co-infected patients using serum fibrosis markers: the SHASTA index. J Hepatol 2005; 43: 78-84.
26. Loko MA, Castera L, Dabis F, et al. Validation and comparison of simple noninvasive indexes for predicting liver fibrosis in HIV-HCV-coinfected patients: ANRS CO3 Aquitaine cohort. Am J Gastroenterol 2008; 103: 1973-80.
27. Macias J, Giron-Gonzalez JA, Gonzalez-Serrano M, et al. Prediction of liver fibrosis in human immunodeficiency virus/hepatitis C virus coinfected patients by simple non-invasive indexes. Gut 2006; 55: 409-14.
28. Nunes D, Fleming C, Offner G, et al. HIV infection does not affect the performance of noninvasive markers of fibrosis for the diagnosis of hepatitis C virus-related liver disease. J Acquir Immune Defic Syndr 2005; 40: 538-44.
29. Shire NJ, Rao MB, Succop P, et al. Improving noninvasive methods of assessing liver fibrosis in patients with hepatitis C virus/human immunodeficiency virus co-infection. Clin Gastroenterol Hepatol 2009; 7: 471-80, e1-2.
30. Trang T, Petersen JR, Snyder N,. Non-invasive markers of hepatic fibrosis in patients co-infected with HCV and HIV: comparison of the APRI and FIB-4 index. Clin Chim Acta 2008; 397: 51-4.
31. Batts KP, Ludwig J,. Chronic hepatitis. An update on terminology and reporting. Am J Surg Pathol 1995; 19: 1409-17.
32. Ghany MG, Strader DB, Thomas DL, Seeff LB,. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology (Baltimore, Md.) 2009; 49: 1335-74.
33. Zou KH, O'Malley AJ, Mauri L,. Receiver-operating characteristic analysis for evaluating diagnostic tests and predictive models. Circulation 2007; 115: 654-7.
34. DeLong ER, DeLong DM, Clarke-Pearson DL,. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988; 44: 837-45.
35. Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology (Baltimore, Md.) 2006; 43: 1317-25.
36. Smith JO, Sterling RK,. Systematic review: non-invasive methods of fibrosis analysis in chronic hepatitis C. Aliment Pharmacol Ther 2009; 30: 557-76.
37. Shaheen AA, Myers RP,. Diagnostic accuracy of the aspartate aminotransferase-to-platelet ratio index for the prediction of hepatitis C-related fibrosis: a systematic review. Hepatology (Baltimore, Md.) 2007; 46: 912-21.
38. Lieber CS, Weiss DG, Morgan TR, Paronetto F,. Aspartate aminotransferase to platelet ratio index in patients with alcoholic liver fibrosis. Am J Gastroenterol 2006; 101: 1500-8.
39. Poynard T, Munteanu M, Imbert-Bismut F, et al. Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis C. Clin Chem 2004; 50: 1344-55.